Payment overview · 2025
General Payments
$746.39
37 reported records · 15 companies
Healthcare provider profile · identity verified
Angelo Mallozzi, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · STAMFORD, CT · NPI 1689768558
Verified facts
What the public records show
CMS Open Payments records show Angelo Mallozzi, M.D. received $746.39 in general payments during 2025 across 37 reported records.
PFIZER INC. accounted for 25.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Mounjaro, Ozempic, Paxlovid, Rexulti.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Mounjaro by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 218 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $187.10 | 25.1% | 9 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $86.62 | 11.6% | 4 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $82.43 | 11.0% | 4 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $59.58 | 8.0% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $44.21 | 5.9% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $40.45 | 5.4% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $36.98 | 5.0% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $36.27 | 4.9% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $32.38 | 4.3% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $31.15 | 4.2% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $27.53 | 3.7% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $22.38 | 3.0% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $21.39 | 2.9% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $20.66 | 2.8% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $17.26 | 2.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $746.39 | 37 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $124.74 | 6 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $120.15 | 5 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $120.15 | 5 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $82.43 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $67.52 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $67.52 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $63.80 | 3 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $59.58 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $44.21 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $43.52 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $36.98 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $36.98 | 2 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $35.99 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $32.38 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $31.15 | 2 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $27.61 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $26.37 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $22.73 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $22.38 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $21.39 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $20.66 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $17.72 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $17.26 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 218 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 86 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 14 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
60 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
86 | 16 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
218 | 35 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 894 | 226 |
| Amlodipine Besylate | Amlodipine Besylate | 636 | 168 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 575 | 162 |
| Levothyroxine Sodium | Levothyroxine Sodium | 403 | 98 |
| Metoprolol Succinate | Metoprolol Succinate | 314 | 84 |
| Losartan Potassium | Losartan Potassium | 279 | 80 |
| Trazodone Hcl | Trazodone Hcl | 244 | 55 |
| Lisinopril | Lisinopril | 236 | 59 |
| Eliquis | Apixaban | 218 | 35 |
| Pantoprazole Sodium | Pantoprazole Sodium | 212 | 51 |
| Gabapentin | Gabapentin | 204 | 49 |
| Metformin Hcl | Metformin Hcl | 204 | 59 |
| Alprazolam | Alprazolam | 189 | 52 |
| Tamsulosin Hcl | Tamsulosin Hcl | 185 | 51 |
| Escitalopram Oxalate | Escitalopram Oxalate | 182 | 42 |
| Hydrochlorothiazide | Hydrochlorothiazide | 176 | 41 |
| Omeprazole | Omeprazole | 170 | 44 |
| Metformin Hcl Er | Metformin Hcl | 167 | 52 |
| Furosemide | Furosemide | 162 | 35 |
| Sertraline Hcl | Sertraline Hcl | 160 | 27 |
| Simvastatin | Simvastatin | 158 | 46 |
| Allopurinol | Allopurinol | 140 | 38 |
| Ezetimibe | Ezetimibe | 136 | 33 |
| Zolpidem Tartrate | Zolpidem Tartrate | 130 | 32 |
| Pravastatin Sodium | Pravastatin Sodium | 120 | 33 |
| Januvia | Sitagliptin Phosphate | 117 | 25 |
| Famotidine | Famotidine | 112 | 34 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 104 | 32 |
| Fluticasone Propionate | Fluticasone Propionate | 94 | 35 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 94 | 30 |
| Montelukast Sodium | Montelukast Sodium | 93 | 19 |
| Valsartan | Valsartan | 93 | 26 |
| Fluoxetine Hcl | Fluoxetine Hcl | 91 | 24 |
| Ozempic | Semaglutide | 86 | 16 |
| Mirtazapine | Mirtazapine | 85 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 84 | 19 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 83 | 23 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 82 | 26 |
| Carvedilol | Carvedilol | 80 | 17 |
| Meloxicam | Meloxicam | 72 | 36 |
| Metoprolol Tartrate | Metoprolol Tartrate | 72 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 68 | 18 |
| Ramipril | Ramipril | 66 | 16 |
| Donepezil Hcl | Donepezil Hcl | 62 | 16 |
| Lorazepam | Lorazepam | 61 | 17 |
| Clonazepam | Clonazepam | 60 | 13 |
| Myrbetriq | Mirabegron | 60 | suppressed |
| Potassium Chloride | Potassium Chloride | 59 | 12 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 56 | 16 |
| Finasteride | Finasteride | 56 | 15 |
| Glipizide | Glipizide | 56 | 19 |
| Xarelto | Rivaroxaban | 56 | 11 |
| Glimepiride | Glimepiride | 55 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 54 | 14 |
| Prednisone | Prednisone | 54 | 22 |
| Tradjenta | Linagliptin | 54 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 53 | 21 |
| Quetiapine Fumarate | Quetiapine Fumarate | 53 | 11 |
| Irbesartan | Irbesartan | 52 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 50 | 21 |
| Jardiance | Empagliflozin | 50 | suppressed |
| Atenolol | Atenolol | 46 | 12 |
| Meclizine Hcl | Meclizine Hcl | 46 | 23 |
| Tramadol Hcl | Tramadol Hcl | 45 | 15 |
| Memantine Hcl | Memantine Hcl | 44 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 44 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 43 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 42 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 40 | 27 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 40 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 40 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 38 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 38 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 37 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 36 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 33 | suppressed |
| Nystatin | Nystatin | 33 | 14 |
| Risperidone | Risperidone | 33 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 33 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 30 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 28 | 13 |
| Linzess | Linaclotide | 28 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 28 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 27 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 27 | 21 |
| Folic Acid | Folic Acid | 27 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 26 | suppressed |
| Amoxicillin | Amoxicillin | 26 | 20 |
| Celecoxib | Celecoxib | 24 | suppressed |
| Latanoprost | Latanoprost | 24 | suppressed |
| Synthroid | Levothyroxine Sodium | 23 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 23 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 22 | suppressed |
| Mounjaro | Tirzepatide | 22 | suppressed |
| Nifedipine Er | Nifedipine | 22 | suppressed |
| Colchicine | Colchicine | 21 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 21 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 21 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 20 | suppressed |
| Ingrezza | Valbenazine Tosylate | 20 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 20 | suppressed |
| Ibuprofen | Ibuprofen | 19 | suppressed |
| Methotrexate | Methotrexate Sodium | 19 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 19 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 18 | suppressed |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Nadolol | Nadolol | 18 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 18 | suppressed |
| Azithromycin | Azithromycin | 17 | 15 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 17 | suppressed |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 17 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 16 |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Timolol Maleate | Timolol Maleate | 17 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Aripiprazole | Aripiprazole | 15 | suppressed |
| Bupropion Xl | Bupropion Hcl | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Anastrozole | Anastrozole | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Telmisartan | Telmisartan | 14 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 13 | suppressed |
| Belsomra | Suvorexant | 13 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| Humulin N Kwikpen | Insulin Nph Human Isophane | 13 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Cephalexin | Cephalexin | 12 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 12 | suppressed |
| Diovan | Valsartan | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 11 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 11 | suppressed |
| Gemtesa | Vibegron | 11 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 11 | suppressed |
| Paxlovid (Eua) | Nirmatrelvir/Ritonavir | 11 | 11 |
| Rexulti | Brexpiprazole | 11 | suppressed |
| Rivastigmine | Rivastigmine | 11 | suppressed |
| Spironolactone | Spironolactone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $746.39 · 37 records | PFIZER INC. | ABRYSVO, Auvelity, BREZTRI, COMIRNATY, Cologuard Collection Kit, ELIQUIS, ENTRESTO, FARXIGA, IBSRELA, Kerendia, LEQVIO, MOUNJARO, NEXLETOL, NURTEC ODT, Ozempic, PAXLOVID, PREVNAR 20, REXULTI, Rybelsus, SHINGRIX, Veozah, XIFAXAN, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error